Advertisement

Immunoscintigraphy of Ovarian Cancer by Means of HMFG2 Monoclonal Antibody

  • M. Granowska
  • C. C. Nimmon
  • K. E. Britton
Conference paper

Abstract

Human milk fat globule 2 (HMFG2) antibody is a monoclonal antibody, class IgG1, against the HMFG protein, which is a large glycoprotein (300 KD). It is present on the epithelial surface membrane lining of the duct of the breast, the crypts of the colon, and the inside lining of ovarian follicles [1, 2].

Keywords

Ovarian Cancer Biopsy Site Anterior View Imperial Cancer Research Fund Diethylene Triamine Penta Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arklie J, Taylor-Papadimitriou J, Bodmer WR, Egan M, Millis R (1981) Different antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers. Int J Cancer 28:23–29PubMedCrossRefGoogle Scholar
  2. 2.
    Burchell J, Durbin H, Taylor-Papadimitriou J (1983) Complexity of expression of antigenic determination, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells. J Immunol 131:503–513Google Scholar
  3. 3.
    Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RC, Bodmer WR (1981) Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 28:17–21PubMedCrossRefGoogle Scholar
  4. 4.
    Hnatowich DJ, Layne WW, Childs RL, Lanteigne D, Davis MA (1983) Radioactive labelling of antibody: a simple and efficient method. Science 220:613–615PubMedCrossRefGoogle Scholar
  5. 5.
    Granowska M, Shepherd J, Mather S, Carroll MJ, Flatman WD, Nimmon CC, Taylor-Papadimitriou J, Ward B, Home T, Britton KE (1984) A prospective study of radioimmunoscintigraphy with 123-I monoclonal antibody in 26 patients with suspected ovarian cancer. Eur J Nucl Med 9:A61Google Scholar
  6. 6.
    Granowska M, Britton KE, Shepherd J (1983) The detection of ovarian cancer using 123I monoclonal antibody. Radiobiol Radiother (Berl) 25:153–160Google Scholar
  7. 7.
    Granowska M, Shepherd J, Britton KE, Ward B, Mather S, Taylor-Papadimitriou J, Epenetos AA, Carroll MJ, Nimmon CC, Hawkins LA, Flatman WD, Home T, Bodmer WR (1984) Ovarian cancer: diagnosis using 123-I monoclonal antibody in comparison with surgical findings. Nucl Med Commun 5:485–499PubMedCrossRefGoogle Scholar
  8. 8.
    Carroll MJ, Flatman WD, Nimmon CC, Granowska M, Britton KE (1984) Congruent image registration as a prerequisite for detecting changes during radioimmunoscintigraphy. Nucl Med Commun 5:230–231 (Abs)Google Scholar
  9. 9.
    Nimmon CC, Carroll MJ, Flatman WD, Marsden P, Granowska M, Home T, Britton KE (1984) Spatial probability mapping of temporal change: application to gamma camera quality control and immunoscintigraphy. Nucl Med Commun 5:231 (Abs)Google Scholar
  10. 10.
    Granowska M, Pring DW, Nimmon CC, Shepherd J, Ward B, Singh P, Mather S, Bomanji J, Slevin ML, Britton KE (1985) Kinetic analysis of radioimmunoscintigraphy, RIS, using probability mapping: comparison with multiple biopsy findings in ovarian cancer. Proc. Europ. Nucl. Med. Cong. London 1985. Eur J Nucl Med 11:A7 (Abs)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • M. Granowska
    • 1
  • C. C. Nimmon
  • K. E. Britton
  1. 1.Dept. of Nuclear MedicineSt. Bartholomew’s HospitalWest Smithfield, LondonUK

Personalised recommendations